The Spectrum of Statin Therapy in Hyperlipidemic Children

 

 Buy Article Permissions and Reprints

ABSTRACT

The recommended therapy of hypercholesterolemia in children consists of dietary modification and bile acid-binding resins. Unfortunately, the lipid-lowering efficacy of bile acid-binding resins is modest, and moreover, long-term compliance is poor because of side effects. In contrast, hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) are widely used in adults and are considered to be the first choice in the treatment of hypercholesterolemia in that age category. In the last few years, several randomized trials have been conducted to evaluate the efficacy, safety, and tolerability of statin therapy in both children and adolescents. In this article, we review statin therapy in hypercholesterolemic children in terms of efficacy, safety, pharmacokinetics, and psychosocial functioning. Statins are not only effective in reducing low-density lipoprotein cholesterol levels in children with familial hypercholesterolemia but also improve endothelial function and reduce the progressive thickening of the intima media complex of the carotid arteries. Statins seem safe at the longer term in children in terms of plasma levels of liver enzymes and liver function, creatine kinase levels, and muscle function, as well as growth and sexual development. Long-term follow-up studies are needed to assess whether statin treatment started early in children with familial hypercholesterolemia can prevent future cardiovascular events.

REFERENCES

• 1 Goldstein J L, Hobbs H H, Brown H S. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D The metabolic basis of inherited disease New York; McGraw-Hill 2001: 2863-2913
  Google Scholar
• 2 Brown M S, Goldstein J L. Receptor-mediated control of cholesterol metabolism.  Science. 1976;  191 150-154
  PubMedGoogle Scholar
• 3 Celermajer D S, Sorensen K E, Gooch V M et al.. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.  Lancet. 1992;  340 1111-1115
  CrossrefPubMedGoogle Scholar
• 4 Sorensen K E, Celermajer D S, Georgakopoulos D et al.. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level.  J Clin Invest. 1994;  93 50-55
  CrossrefPubMedGoogle Scholar
• 5 Mietus-Snyder M, Malloy M J. Endothelial dysfunction occurs in children with two genetic hyperlipidemias: improvement with antioxidant vitamin therapy.  J Pediatr. 1998;  133 35-40
  PubMedGoogle Scholar
• 6 Aggoun Y, Bonnet D, Sidi D et al.. Arterial mechanical changes in children with familial hypercholesterolemia.  Arterioscler Thromb Vasc Biol. 2000;  20 2070-2075
  PubMedGoogle Scholar
• 7 de Jongh S, Lilien M R, Bakker H D, Hutten B A, Kastelein J JP, Stroes E SG. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia.  Atherosclerosis. 2002;  163 193-197
  CrossrefPubMedGoogle Scholar
• 8 Pauciullo P, Iannuzzi A, Sartorio R et al.. Increased intima-media thickness of the common carotid artery in hypercholesterolemic children.  Arterioscler Thromb. 1994;  14 1075-1079
  PubMedGoogle Scholar
• 9 Tonstad S, Joakimsen O, Stensland-Bugge E et al.. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects.  Arterioscler Thromb Vasc Biol. 1996;  16 984-991
  PubMedGoogle Scholar
• 10 Virkola K, Pesonen E, Akerblom H K, Siimes M A. Cholesterol and carotid artery wall in children and adolescents with familial hypercholesterolaemia: a controlled study by ultrasound.  Acta Paediatr. 1997;  86 1203-1207
  PubMedGoogle Scholar
• 11 Jarvisalo M J, Jartti L, Nanto-Salonen K et al.. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children.  Circulation. 2001;  104 2943-2947
  PubMedGoogle Scholar
• 12 Wiegman A, Groot E, Hutten B A et al.. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia.  Lancet. 2004;  363 369-370
  CrossrefPubMedGoogle Scholar
• 13 American Academy of Pediatrics . National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents.  Pediatrics. 1992;  89 525-584
  PubMedGoogle Scholar
• 14 Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia.  J Pediatr. 1996;  129 42-49
  PubMedGoogle Scholar
• 15 Glueck C J, Mellies M J, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia.  Pediatrics. 1986;  78 338-348
  PubMedGoogle Scholar
• 16 Marks D, Thorogood M, Neil H A, Humphries S E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.  Atherosclerosis. 2003;  168 1-14
  CrossrefPubMedGoogle Scholar
• 17 Stein E A, Illingworth D R, Kwiterovich Jr P O et al.. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.  JAMA. 1999;  281 137-144
  CrossrefPubMedGoogle Scholar
• 18 Lambert M, Lupien P J, Gagne C et al.. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.  Pediatrics. 1996;  97 619-628
  PubMedGoogle Scholar
• 19 Knipscheer H C, Boelen C C, Kastelein J J et al.. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.  Pediatr Res. 1996;  39 867-871
  PubMedGoogle Scholar
• 20 Couture P, Brun L D, Szots F et al.. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.  Arterioscler Thromb Vasc Biol. 1998;  18 1007-1012
  PubMedGoogle Scholar
• 21 de Jongh S, Ose L, Szamosi T et al.. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin.  Circulation. 2002;  106 2231-2237
  CrossrefPubMedGoogle Scholar
• 22 Dirisamer A, Hachemian N, Bucek R A, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation.  Eur J Pediatr. 2003;  162 421-425
  PubMedGoogle Scholar
• 23 Wiegman A, Hutten B A, de Groot E et al.. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.  JAMA. 2004;  292 331-337
  CrossrefPubMedGoogle Scholar
• 24 McCrindle B W, Ose L, Marais A D. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.  J Pediatr. 2003;  143 74-80
  CrossrefPubMedGoogle Scholar
• 25 Athyros V G, Papageorgiou A A, Kontopoulos A G. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia.  Atherosclerosis. 2002;  163 205-206
  CrossrefPubMedGoogle Scholar
• 26 Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood.  Drugs Exp Clin Res. 1999;  25(1) 23-28
  PubMedGoogle Scholar
• 27 Ducobu J, Brasseur D, Chaudron J M et al.. Simvastatin use in children.  Lancet. 1992;  339 1488
  PubMedGoogle Scholar
• 28 Schachinger V, Britten M B, Zeiher A M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.  Circulation. 2000;  101 1899-1906
  CrossrefPubMedGoogle Scholar
• 29 Neunteufl T, Heher S, Katzenschlager R et al.. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain.  Am J Cardiol. 2000;  86 207-210
  CrossrefPubMedGoogle Scholar
• 30 Suwaidi J A, Hamasaki S, Higano S T, Nishimura R A, Holmes Jr D R, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.  Circulation. 2000;  101 948-954
  CrossrefPubMedGoogle Scholar
• 31 Stroes E S, Koomans H A, de Bruin T W, Rabelink T J. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication.  Lancet. 1995;  346 467-471
  CrossrefPubMedGoogle Scholar
• 32 Holm T, Andreassen A K, Ueland T et al.. Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients.  Am J Cardiol. 2001;  87 815-818
  CrossrefPubMedGoogle Scholar
• 33 Smilde T J, van Wissen S, Wollersheim H, Trip M D, Kastelein J J, Stalenhoef A F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.  Lancet. 2001;  357 577-581
  CrossrefPubMedGoogle Scholar
• 34 Wassmann S, Ribaudo N, Faul A, Laufs U, Bohm M, Nickenig G. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels < 130 mg/dl.  Am J Cardiol. 2004;  93 84-88
  CrossrefPubMedGoogle Scholar
• 35 de Jongh S, Lilien M R, op't Roodt J, Stroes E S, Bakker H D, Kastelein J J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia.  J Am Coll Cardiol. 2002;  40 2117-2121
  CrossrefPubMedGoogle Scholar
• 36 Staffa J A, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis.  N Engl J Med. 2002;  346 539-540
  CrossrefPubMedGoogle Scholar
• 37 Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).  Eur J Clin Pharmacol. 2001;  57 357-364
  CrossrefPubMedGoogle Scholar
• 38 Hedman M, Neuvonen P J, Neuvonen M, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia.  Clin Pharmacol Ther. 2003;  74 178-185
  CrossrefPubMedGoogle Scholar
• 39 Wiersma H E, Wiegman A, Koopmans R P et al.. Steady-state pharmacokinetics of pravastatin in children with familial hypercholesterolemia.  Clin Drug Invest. 2004;  24 113-120
  PubMedGoogle Scholar
• 40 Froese A P, Rose V, Allen D M. Emotional implications of primary familial hyperlipoproteinemia in childhood and adolescence.  Pediatrics. 1980;  65 469-472
  PubMedGoogle Scholar
• 41 Tonstad S, Novik T S, Vandvik I H. Psychosocial function during treatment for familial hypercholesterolemia.  Pediatrics. 1996;  98 249-255
  PubMedGoogle Scholar
• 42 Rosenthal S L, Knauer-Black S, Stahl M P, Catalanotto T J, Sprecher D L. The psychological functioning of children with hypercholesterolemia and their families. A preliminary investigation.  Clin Pediatr (Phila). 1993;  32 135-141
  PubMedGoogle Scholar
• 43 de Jongh S, Kerckhoffs M C, Grootenhuis M A, Bakker H D, Heymans H S, Last B F. Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents.  Acta Paediatr. 2003;  92 1096-1101
  CrossrefPubMedGoogle Scholar
• 44 Hennermann J B, Herwig J, Marz W, Asskali F, Bohles H J. Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy.  Eur J Pediatr. 1998;  157 912-918
  CrossrefPubMedGoogle Scholar
• 45 Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia.  Arch Dis Child. 1996;  74 157-160
  PubMedGoogle Scholar
• 46 Briggs G G, Freeman R K, Yaffe S J. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. Philadelphia; Lippincott Williams & Wilkins 2002
  Google Scholar

 Prof.
 Dr.
J.J. P Kastelein

Department of Vascular Medicine, Academic Medical Centre

Meibergdreef 9 Room F4-159.2

1105 AZ Amsterdam, The Netherlands